clinical trial · NCT04628585
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
Sickle Cell DiseaseSafety and efficacy assessments
brief summary
This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in the study.
started
Oct 21, 2020
primary completion
Jan 1, 2038
completion
Jan 1, 2038
last updated
Mar 20, 2025
official title
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol